You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中恒集團(600252.SH):子公司藥品通過仿製藥一致性評價

格隆匯7月6日丨中恒集團(600252.SH)公佈,公司控股子公司重慶萊美藥業股份有限公司(簡稱“萊美藥業”)於近日收到國家藥品監督管理局核准簽發的規格為5ml:30mg的紫杉醇注射液的《藥品補充申請批准通知書》。

紫杉醇注射液適用於進展期卵巢癌的一線和後繼治療;淋巴結陽性的乳腺癌患者在含阿黴素標準方案聯合化療後的輔助治療;轉移性乳腺癌聯合化療失敗或者輔助化療6個月內復發的乳腺癌患者;非小細胞肺癌患者的一線治療;艾滋病(AIDS)相關性卡波氏肉瘤(Kaposi’s sarcoma)的二線治療。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account